请介绍一下成都先导的业务发展历程和核心技术。 成都先导成立于 2012 年，专注于新分子的产生及其在药物项目中的应用。公 司创始人李静选择了具有发展潜力但仍需探索的 DNA 编码化合物库技术。该技 术旨在解决如何找到能够调控特定靶点的新分子的问题。通过这一技术，公司 可以快速且低成本地合成大量分子，目前已合成 1.2 万亿个小分子。这些小分 子可用于筛选与特定靶点匹配的苗头化合物，并进一步优化以开发成药。 成都先导在新药研发中具体扮演什么角色？ 成都先导主要处于新药研发的前端环节，通过 DNA 编码化合物库技术，为制药 企业提供靶点筛选服务。公司与国际大型制药企业如辉瑞、强生，以及前沿生 物技术公司合作，利用其庞大的小分子库和筛选方法，找到与客户提供的靶点 匹配的活性化合物，并将这些化合物授权给客户进行后续开发，包括申请专利、 成都先导 20250225 摘要 • 成都先导专注于新药研发前端，利用 DNA 编码化合物库（DEL）技术，为 药企提供靶点筛选服务，已与辉瑞、强生等合作，成功率超 70%，涵盖经 典和蓝海靶点，提供活性苗头化合物。 • 公司构建了全球最大的 1.2 万亿小分子库，通过组合化学和 DN ...

成都先导药物开发股份有限公司关于股东 重庆渤溢新天股权投资基金合伙企业（有限合伙） 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 证券代码：688222 证券简称：成都先导 公告编号：2025-001 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持计划实施前股东持股的基本情况 本次减持计划实施前，成都先导药物开发股份有限公司（以下简称"公司"） 股东重庆渤溢新天股权投资基金合伙企业（有限合伙）（以下简称"渤溢新天"） 持有公司股份 6,217,637 股，占公司总股本的 1.55%。 上述股份为公司 IPO 前取得股份，该部分股份于 2021 年 4 月 16 日起解禁 上市流通。渤溢新天减持原因系该合伙企业即将到期清算。 减持计划的实施结果情况 公司于 2024 年 11 月 20 日在上海证券交易所网站披露《成都先导药物开发 股份有限公司关于股东钧天创业投资有限公司、重庆渤溢新天股权投资基金合伙 企业（有限合伙）减持股份计划公告》（公告编号：2024-037）： 渤溢新天拟通过集中竞价交易或大宗交易的方式减持 ...

像智能智能智能智能AI这个部分的话然后以及已经有了一些已知分子的这个发色菠萝也是现在新疆发现的一个非常重要的一个途径 那么我们回顾来说的话对于小分子的这个就是源头的这个新药发现的话它实际上本质就是从这种浩瀚的这种化学空间里头来进行一个寻找新药的一个起点那么如何有效的找到这个起点不管是实验科学的不断的技术迭代更新也好还是人工智能技术的一个不断的迭代更新也好本质上都是希望能够就是 最快最有效的能够针对一个特定的一个把点然后找到他的一个心要的一个起点 那么我们找到一个起点它去它是一个方式那么除了找到之外的话我们还希望的话就是说找到一个好的那么就是说如何能够找到和如何能够找到一个好的实际上本质就是一个新有研发最核心的两个问题那么什么样的项目是找都找不到吗就是我们现在其实就经过了这么几十年的一个百项要务的一个研发我们知道像有很多 这种男乘腰的靶点最经典的就是蛋白蛋白相互作用然后还有一些转移因子磨蛋白离子通道这些都属于非常挑战的靶点类型那么对于这些类型的蛋白来说的话它可能就是找到本身就是一个非常挑战的一个任务 那么第二个的话就是对于那些相对来说比较容易找到的这些分子他还有什么样的一些问题呢其实就是临床期间的一个转化小分子 ...

成都先导药物开发股份有限公司 关于自愿披露"HG146 胶囊"II 期临床试验完成 首例受试者入组公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 证券代码：688222 证券简称：成都先导 公告编号：2024-038 一、 项目基本情况 HG146（HDAC I/IIb 亚型选择性小分子抑制剂）是成都先导开发的选择性的 I 类和 IIb 类组蛋白去乙酰化酶（HDAC）的抑制剂，于 2018 年 4 月和 2021 年 4 月分别获批开展针对多发性骨髓瘤适应症和晚期实体瘤或淋巴瘤适应症的临床 研究许可。截至目前，成都先导已完成 HG146 的 I 期临床研究，成功获得 HG146 在人体的安全性、耐受性、初步有效性及药代动力学特征，并获得 RP2D（临床 II 期推荐剂量），用于开发能从 HG146 获益的适应症。 1 近日，成都先导药物开发股份有限公司（以下简称"成都先导"或"公司"） 自主研发的1.1类抗肿瘤创新药"HG146胶囊"（以下简称"HG146"）（药品代 码：HG146）用于治疗复发或转 ...

证券代码：688222 证券简称：成都先导 公告编号：2024-039 成都先导药物开发股份有限公司 关于股东钧天创业投资有限公司集中竞价 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 公司于 2024 年 12 月 27 日收到股东钧天创投出具的相关告知函，截至本公 告披露日，钧天创投在本减持计划期间通过集中竞价交易方式累计减持其所持有 的公司股份 1,831,448 股，占公司总股本比例为 0.46%。本次权益变动后，钧天 创投不再持有公司股份，减持计划实施完毕。 | 股东名称 | 股东身份 | 持股数量 | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | | | | （股） | | | | 钧天创业 | 5%以下股东 | 1,831,448 | 0.46% | IPO 前取得：1,831,448 | | 投资有限 | | | | 股 | | 公司 | | | | | 重要内容提示： 本次减持计划实施前股东持股的基本情况 本次减持计划实 ...

证券代码：688222 证券简称：成都先导 公告编号：2024-037 成都先导药物开发股份有限公司 关于股东钧天创业投资有限公司、重庆渤溢新天 股权投资基金合伙企业（有限合伙） 减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持股东的持股基本情况 截至本公告披露日，公司股东钧天创投持有公司股份 1,831,448 股，占公司 总股本的 0.46%；钧天创投与公司股东深圳市钧天创业投资有限公司（以下简称 "钧天投资"）均由深圳市九野钧天创业投资管理有限公司担任基金管理人，二者 构成一致行动关系，钧天投资持有公司股份 14,102,516 股，占公司总股本的 3.52%。 钧天投资、钧天创投合计持有公司股份 15,933,964 股，占公司总股本的 3.98%。 1 本次减持计划的股东钧天创业投资有限公司（以下简称"钧天创投"）、 重庆渤溢新天股权投资基金合伙企业（有限合伙）（以下简称"渤溢新 天"）有关于减持意向的承诺： （1） 减持方式：减持成都先导药物开发股份有限公司 ...

Investment Rating - The report maintains an "Outperform the Market" rating for the company [5][67][68] Core Views - The company has successfully established four core platforms: DEL, FBDD/SBDD, STO, and TPD, focusing on small molecules and nucleic acid drugs, which enhances its competitiveness in the CRO field [3][67] - The company is expected to gradually recover its performance, with projected revenues of 4.47 billion, 5.56 billion, and 7.10 billion yuan for 2024, 2025, and 2026, respectively, representing year-on-year growth rates of 20.3%, 24.5%, and 27.6% [3][67] - The reasonable price range for the company's stock is estimated to be between 13.48 and 14.85 yuan, indicating a potential upside of 3% to 14% from the current price [3][68] Summary by Sections Financial Performance - In the first three quarters of 2024, the company achieved a revenue of 298 million yuan, a year-on-year increase of 21.4%, and a net profit attributable to shareholders of 30 million yuan, up 64.7% [1][6] - The company’s revenue for the full year of 2023 was 371 million yuan, reflecting a growth of 12.6% compared to the previous year [1][4] Revenue Breakdown - The revenue from the DEL platform was 122 million yuan, an increase of 2.93%, while the FBDD/SBDD platform generated 93 million yuan, up 58.21% [8][11] - The STO platform achieved a revenue of 38 million yuan, growing by 39.81%, and the TPD platform brought in 15 million yuan, an increase of 47.92% [8][11] Profitability Metrics - The gross margin for the first three quarters of 2024 was 49.3%, an increase of 5.63 percentage points, and the net profit margin was 10.1%, up 2.66 percentage points [13][14] - The company’s net profit attributable to shareholders is projected to reach 50 million, 63 million, and 83 million yuan for 2024, 2025, and 2026, respectively, with growth rates of 21.6%, 27.3%, and 31.5% [3][67] Market Position and Competitive Advantage - The company possesses over 1.2 trillion compounds in its drug seed library, making it a leader in the new drug development CRO industry [2][15] - The integration of AI and automation with existing platforms is expected to enhance drug discovery capabilities and optimize processes [45][46] Future Outlook - The company is expected to continue expanding its core platforms and enhancing its technological capabilities, which will support its growth trajectory in the coming years [3][67] - The strategic partnerships and collaborations with international pharmaceutical companies further solidify the company's position in the market [31][41]

证券代码：688222 证券简称：成都先导 公告编号：2024-036 成都先导药物开发股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 11 月 5 日(星期二)至 11 月 11 日(星期一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过投资者 关系邮箱（investors@hitgen.com）进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 成都先导药物开发股份有限公司（以下简称"公司"）已于 2024 年 10 月 26 日在上海证券交易所网站（www.sse.com.cn）披露公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 11 月 12 日(星期二) 14:00-15:00 举行 2024 年第三季度业绩说明会，就投资者 关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [15]. Core Insights - The company is showing a gradual recovery in Q3, with a significant increase in revenue and profit, driven by the growth of its DEL platform and ongoing improvements in its drug discovery capabilities [1][2]. - The company achieved a revenue of 1.04 billion yuan in Q3 2024, representing a year-on-year growth of 14.96%, and a net profit of 199.2 million yuan, up 59.82% year-on-year [1]. - The report highlights the company's strong pipeline of new drug projects and the successful implementation of new technology platforms, which are expected to contribute to long-term growth [1][2]. Financial Performance Summary - **Revenue Forecasts**: - 2022A: 329.65 million yuan - 2023A: 371.32 million yuan (growth rate: 12.64%) - 2024E: 434.94 million yuan (growth rate: 17.13%) - 2025E: 518.31 million yuan (growth rate: 19.17%) - 2026E: 625.55 million yuan (growth rate: 20.69%) [1] - **Net Profit Forecasts**: - 2022A: 25.27 million yuan - 2023A: 40.72 million yuan (growth rate: 61.16%) - 2024E: 50.23 million yuan (growth rate: 23.36%) - 2025E: 63.12 million yuan (growth rate: 25.67%) - 2026E: 80.36 million yuan (growth rate: 27.31%) [1] - **Earnings Per Share (EPS)**: - 2022A: 0.06 yuan - 2023A: 0.10 yuan - 2024E: 0.13 yuan - 2025E: 0.16 yuan - 2026E: 0.20 yuan [1] - **Valuation Ratios**: - P/E ratio is projected to decrease from 225.03 in 2022A to 70.75 in 2026E, indicating improving valuation as earnings grow [1]. - P/B ratio is expected to decline from 4.37 in 2022A to 3.68 in 2026E [1]. Market Comparison - The company’s market capitalization is approximately 5.69 billion yuan, with a share price of 14.19 yuan as of October 28, 2024 [1]. - The report notes that the overall market trend is showing a recovery, with the company’s performance improving relative to its peers in the industry [1]. Business Development - The company is expanding its capabilities in drug discovery through the establishment of new technology platforms, including DEL and AI/ML, which are expected to enhance its competitive edge and drive future growth [1][2]. - The report emphasizes the importance of the company’s diverse drug pipeline and its ability to adapt to market demands, which positions it well for sustained growth [1].

Financial Performance - The company's operating revenue for Q3 2024 was ¥103,549,898.82, representing a year-over-year increase of 14.96%[2] - The net profit attributable to shareholders for Q3 2024 was ¥19,922,553.96, reflecting a significant increase of 59.82% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥15,252,346.18, with a year-over-year increase of 39,114.40%[2] - The basic earnings per share for Q3 2024 was ¥0.05, up 66.67% from the previous year[3] - Total operating revenue for the first three quarters of 2024 reached RMB 298,269,775.63, an increase of 21.3% compared to RMB 245,729,314.33 in the same period of 2023[13] - Net profit for the first three quarters of 2024 was RMB 28,665,735.55, compared to RMB 18,438,333.95 in 2023, representing a growth of 55.5%[15] - The company's operating profit for the first three quarters of 2024 was RMB 26,015,358.54, significantly higher than RMB 7,321,397.06 in the same period last year[15] - The total comprehensive income for the first three quarters of 2024 was RMB 35,378,804.00, compared to RMB 28,129,435.41 in 2023, indicating an increase of 25.9%[16] - Basic earnings per share for the first three quarters of 2024 were RMB 0.08, up from RMB 0.05 in the same period of 2023[16] Research and Development - The total R&D investment for Q3 2024 was ¥20,917,934.89, a decrease of 11.34% compared to the same period last year[3] - The company’s R&D investment accounted for 20.20% of operating revenue in Q3 2024, a decrease of 0.82 percentage points year-over-year[3] - Research and development expenses for the first three quarters of 2024 amounted to RMB 51,651,962.63, a decrease from RMB 58,256,296.89 in 2023, showing a reduction of 11.0%[15] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥1,722,496,578.95, showing a slight decrease of 0.41% from the end of the previous year[3] - The company's total assets as of September 30, 2024, amount to approximately 1.72 billion RMB, a slight decrease from 1.73 billion RMB at the end of 2023[12] - The total current liabilities decreased to approximately 69.28 million RMB from 85.98 million RMB[12] - The company's total liabilities decreased from RMB 346,566,991.96 to RMB 320,757,631.35, a reduction of 7.4%[13] - The total equity attributable to shareholders of the parent company increased from RMB 1,358,124,788.21 to RMB 1,378,326,364.55, reflecting a growth of 1.5%[13] - Deferred income tax liabilities decreased from RMB 17,697,120.28 to RMB 15,905,006.57, a decline of 10.1%[13] Cash Flow - The company reported a net cash flow from operating activities of ¥98,963,885.55 for the year-to-date, an increase of 50.41% compared to the same period last year[2] - In the first three quarters of 2024, the cash inflow from operating activities totaled CNY 341,507,776.40, compared to CNY 310,006,995.10 in the same period of 2023, representing an increase of approximately 10.5%[18] - The net cash flow from investment activities was CNY -687,586.08, a significant improvement from CNY -104,127,887.32 in the previous year, indicating a reduction in cash outflow[18] - The company received CNY 1,590,000,000.00 from investment recoveries, up from CNY 1,254,000,000.00 in the same period last year, marking an increase of approximately 26.7%[18] - The total cash outflow from investment activities was CNY 1,603,054,130.49, compared to CNY 1,369,169,439.17 in the previous year, reflecting an increase of about 17%[18] - The net cash flow from financing activities was CNY -39,033,990.56, worsening from CNY -17,238,002.39 in the same period last year, indicating increased cash outflow[19] - The cash and cash equivalents at the end of the period amounted to CNY 428,952,786.46, up from CNY 305,245,536.37 at the end of the same period last year, representing an increase of approximately 40.5%[19] - The company reported a cash inflow from tax refunds of CNY 14,280,949.99, compared to CNY 8,255,231.44 in the previous year, showing an increase of about 73.5%[18] - The total cash outflow for employee compensation was CNY 128,463,643.88, slightly down from CNY 133,437,780.49 in the previous year, indicating a decrease of about 3.2%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,663, with the top ten shareholders holding significant stakes[8] - JIN LI (李进) holds 81,876,948 shares, representing 20.43% of the total shares[9] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending[9] - There are no significant related party transactions or concerted actions among the top shareholders[9] Other Information - The company received government subsidies amounting to ¥1,723,912.99 in Q3 2024, which is lower than the previous year's amount[4] - The inventory level as of September 30, 2024, is 29.93 million RMB, compared to 28.18 million RMB in the previous year[11] - The company reported a significant increase in long-term equity investments, rising to 14.62 million RMB from 12.38 million RMB[11] - The company has not identified any other important information regarding its operational performance during the reporting period[10] - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting practices[20] - The company experienced a foreign exchange loss of CNY -2,880,259.64, contrasting with a gain of CNY 4,452,847.37 in the same period last year, highlighting a significant change in currency impact[19]